Background: Perioperative vedolizumab (VDZ) and anti-tumour necrosis factor
The sequelae of these infections can be quite severe. In the short term, patients may develop life-threatening sepsis, require reoperations 26 or procedures for abscess drainage, 27, 28 suffer from prolonged ileus or prolonged hospital stay and require hospital readmission. 29 Long-term effects include the need for an ostomy, development of hernias 30 and poor quality of life due to poor bowel function. 31, 32 Considering the devastating consequences of SSIs in this population, judicious and evidence-based selection of pharmacotherapy for patients at high risk for surgical intervention is critical. Given the clinical equipoise from published studies and the mechanistic concerns for post-operative SSI after VDZ exposure, we aimed to compare the risk of post-operative SSI between VDZ-and TNFitreated patients in propensity-matched cohorts using a populationbased dataset.
| METHODS

| Data source
We performed a longitudinal retrospective cohort analysis of IBD 
| Cohort identification and classification
We selected a cohort of patients with: (1) at least one IBD-related Table S1 ). The primary predictor of interest was VDZ infusion within 30 days before surgery compared to TNFi prescription within 30 days before surgery. This 30 day pre-operative window defining "drug exposure" is consistent with the published pharmacokinetics of VDZ. 34 Clinically, this time frame is consistent with patients' real-world TNFi or VDZ maintenance dosing frequency (every 4 weeks) if they were not responding to biologic therapy prior to surgery.
| Propensity score matching
As patients prescribed VDZ may have already failed first-line biologic therapies (suggestive of more severe disease than patients prescribed anti-TNF agents alone), we performed propensity score matching to establish comparable cohorts using risk-modifying clini- 3 | RESULTS
| Patient cohort identification & characteristics
The data for 1933 and 522 837 IBD patients receiving VDZ or TNFi, respectively, were retrieved from in-patient and out-patient claims dataset in Optum. Of these, 573 484 patients were excluded as they did not undergo surgery or had VDZ or TNFi exposure outside the 30-day abdominal surgery date. Ultimately, 94 VDZ and 1725 TNFi IBD patients met criteria for study inclusion. After propensity score matching, we identified and compared 92 VDZ-exposed patients with 94 TNFi-exposed patients, creating a cohort of 186 patients. TNFi groups (P = 0.17).
| Malnutrition is an independent risk factor for SSI
Multivariable analysis showed malnutrition as the sole significant predictor for post-operative SSI (OR 3.1, 95% CI 1.1-8.7, P = 0.03) ( 
| DISCUSSION
Post-operative infectious complications in patients undergoing surgery for IBD-related indications are a major cause of morbidity and increased healthcare resource utilisation. [28] [29] [30] The effects of TNFi or VDZ exposure perioperatively on the risk of infectious complications remains unclear. [6] [7] [8] [9] [10] [11] [12] [13] [14] Understanding the differences in operative risk posed by different biologic agents has become increasingly important, given the numerous competing therapy options after first-line treatment failure. In the largest risk-adjusted cohort analysis to date, we sought to answer this clinically relevant question.
Through propensity-score matching using potential predictors for postoperative infectious complications, we found that SSI risk was not statistically different between TNFi-and VDZ-exposed patients.
Furthermore, in multivariable analysis, malnutrition was the only significant predictor of SSI among multiple well-established risk factors including age, surgical approach, the presence of an ostomy, concomitant immunomodulatory use and corticosteroid exposure.
Patients who were classified as having malnutrition had over a 3-fold increased risk of SSI as a complication.
Our study findings have significant clinical implications, demonstrating the need to optimise nutrition in patients with IBD, who are often chronically malnourished during states of prolonged disease exacerbation. Although the prevalence of malnutrition in IBD by ICD coding from a representative in-patient cohort of IBD patients is 5%-10%, 37 the probability of malnutrition just prior to IBD-related surgery is likely much higher. 38 Previous literature suggests that more than half of all patients may meet criteria for malnutriton at the time of IBD diagnosis. 39 Furthermore, it is likely that malnutrition especially in acute care settings may be under-reported and not diagnosed in patients with IBD. 40, 41 This may be more apparent in patients who have been hospitalised for surgical management of a primary diagnosis. 42, 43 Therefore, we recommend pre-operative measures to optimise nutrition including supportive enteral feeds or parenteral nutrition as indicated.
Exposure to corticosteroids in the perioperative period is a potential risk factor for surgical site infections, although there is some debate in the literature about its effect. 44, 45 In this study, we found that perioperative corticosteroid exposure was associated with a greater risk for surgical site infections in patients with Crohn's disease. Patients exposed to corticosteroids in the perioperative period are more likely to have steroid-refractory disease, so this may also be an indicator of greater clinical disease severity. In conclusion, pre-operative vedolizumab use does not increase post-operative SSI risk as compared to pre-operative TNFi treatment. However, a chart diagnosis of malnutrition is a significant predictor of SSI. While a diagnosis of malnutrition certainly indicates severe overall disease, further prospective research is needed to determine whether this risk can be modified with perioperative interventions to address nutritional status.
